Glaucoma, one of the leading causes of permanent blindness, often does its damage silently – with no noticeable symptoms – as ...

Glaucoma is the second leading cause of blindness in the U.S.A primary screening tool for glaucoma is measurement of IOP. The ...

The product, the iDose TR, is said to be the first long-term sustained release pharmaceutical for the treatment of glaucoma, according to the Aliso Viejo-based medical technology company.

A top heart doctor has revealed the insidious supplements in medicine capsules that could increase your risk of a heart ...

LVPEI inaugurates technology-enabled vision centre in Mandadam village, offering free eye care services and teleconsultation facilities.

Nicox completed the Denali Phase 3 trial for NCX 470, targeting open-angle glaucoma and ocular hypertension. NCX 470 combines ...

Biological age acceleration is associated with an increased risk of glaucoma and elevated intraocular pressure.

Lifitegrast 5.0%, a topical anti-inflammatory therapy, effectively reduces signs and biomarkers of dry eye disease in 12 ...

NAION risk is most significant within the first 12 months of beginning semaglutide, and is highest in patients with additional risk factors.